Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Papillomavirus Infections Clinical Trial

Official title:

A Randomized, Placebo-Controlled Phase II Study of Multiple Dosing Regimens of Intravaginally Administered 851B Gel for the Treatment of Cervical High Risk HPV Infection

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00312286
• Other study ID #: 1547-851B
• Secondary ID: U1111-1127-5771
• Status: Terminated
• Phase: Phase 2
• First received: April 6, 2006
• Last updated: August 16, 2016
• Start date: April 2006
• Est. completion date: June 2008

Study information

• Verified date: August 2016
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationCanada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.

Description:

Cervical cancer is caused by infection with specific genotypes of the human papillomavirus referred to as oncogenic or high-risk human papillomavirus. Current epidemiologic evidence suggests that 80% of sexually active women will become infected during their lifetime with human papillomavirus and 50% of these infections will be due to high-risk human papillomavirus. With US annual rates of cervical cancer now in the range of 13,000/year, a very substantial number of women are left with uncertainty regarding whether their infection will clear spontaneously or progress to cancer.

Subjects participating in this study were required to visit the clinic for approximately 15 or 16 visits, and maintain a diary of self-dosing and menstruation cycles. The total time of participation in this study was approximately 27 months.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 538
• Est. completion date: June 2008
• Est. primary completion date: June 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• A female subject of childbearing potential who is sexually active using contraception.

• Subject is willing to abstain from all sexual contact involving her genitalia for at least 24 hours prior to and 24 hours after study drug administration.

• Subject must be neither pregnant nor lactating from Screening throughout the duration of the study.

• Subject has 1 of the following:

• Menstruating with a stable cycle and has at least 21 non-bleeding days.

• Amenorrheic (due to injectable or extended-cycle contraceptives).

• Subject is willing to refrain from using vaginal douche products during the treatment period and through the Follow-up Month 4 visit.

• Subject has a Pap test interpretation of either low-grade squamous intraepithelial lesions or atypical squamous cells of undetermined significance.

• Subject has a uterine cervical sample that is high-risk human papillomavirus positive.

Exclusion Criteria:

• The Subject has evidence of an uncontrolled, clinically significant medical condition as determined by the investigator.

• The Subject has a history of hemorrhagic diatheses or coagulopathy.

• The Subject has a history of toxic shock syndrome.

• The Subject has received any of the following medications in the timeframes listed below:

• 851 (in any form) or an active (non-placebo) human papillomavirus vaccine at any time prior to the screening visit.

• In the 4 weeks prior to the screening visit the subject has received:

• Interferon therapy or other therapies that promote a proinflammatory immune state, including:

• immunomodulators.

• cytotoxic drugs.

• drugs known to have major organ toxicity.

• Used a vaginal douche 72 hours prior to the screening visit.

• Received any investigational drug within 60 days of Study Day 1.

• Used in the 2 weeks prior to Study Day 1:

• oral or inhaled corticosteroids (>1000 mcg/day, fluticasone propionate >600 mg/day, or equivalent).

• systemic steroids.

• topical drugs to the anogenital area.

• NuvaRing.

• The Subject has a history of hypersensitivity to any components of the gel formulation or to iodine.

• The Subject has given birth or has had a spontaneous or induced abortion within 2 months of Study Day 1.

• The Subject uses an intrauterine device, diaphragm, NuvaRing, or additional contraceptive foam or gel for birth control.

• The Subject has:

• histology read as high-grade cervical intraepithelial neoplasia.

• cytology read as high-grade squamous intraepithelial lesion.

• cytology read as atypical glandular cytological abnormalities.

• cytology read as atypical squamous cells - cannot exclude high grade.

• cervical carcinoma of any type.

• apparent endocervical involvement.

• high-grade vulvar intraepithelial neoplasia.

• high-grade vaginal intraepithelial neoplasia.

• If the limits of a cervical lesion cannot be readily visualized.

• If the limits of the transformation zone cannot be readily visualized.

• The subject has clinical evidence of a vaginal infection or sexually transmitted infection, other than cervical human papillomavirus infection at the Study Day 1 visit.

• The Subject has had a cervical biopsy within 1 month prior to the screening visit.

• The Subject has had any previous ablative or surgical treatment of the cervix within 3 months prior to the screening visit;

• The Subject has a history of alcoholism or substance abuse within 1 year or has current alcohol or substance abuse as assessed by the investigator.

• The Subject has tested positive for human immunodeficiency virus at the screening visit or has evidence of any other immunosuppressive disease.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Papillomavirus Infections

Intervention

Drug:
• 851B
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
• 851B
851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
• 851B
851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
• 851B
851B 3.0% formulation, gel, topically, once a week for 1 cycle.
• 851B
851B 3.0% formulation, gel, topically, once a week for 2 cycles.
• 851B
851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
• 851B
851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
• 851B
851B placebo-matching gel, topically, once a week for 1 cycle.
• 851B
851B placebo-matching gel, topically, twice a week for 1 cycle.
• 851B
851B placebo-matching gel, topically, once a week for 2 cycles.
• 851B
851B placebo-matching gel, topically, twice a week for 2 cycles.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Countries where clinical trial is conducted

United States,  Canada,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to clearance of high-risk human papillomavirus infection.		At each visit	No
Secondary	Proportion of subjects with evidence of regression to normal cytology.		Screening Visit and Follow-up Visits (Months 6, 8, 14, 20, and 26).	No
Secondary	Proportion of subjects with improvement in cervical lesions as rated by the investigator (measured by colposcopy).		At each visit	No
Secondary	Proportion of subjects who develop histological evidence of cervical intraepithelial neoplasia.		Visits 1-3 as assigned by group	No
Secondary	Time to progression of disease to precancer.		Visits 1-3 as assigned by group	No
Secondary	Change in relative light units ratios relative to the positive control from Hybrid Capture 2® assay (semi-quantitatively assessing viral load).		At each visit	No